TLDR
Market Recap: September 8, 2025
On September 8, 2025, Indian equities started the week marginally higher as autos ripped on GST-led price cuts while IT softness capped gains; currency and debt markets were shut for a local holiday, with cash/SLB settlements bunched mid-week. The Sensex closed at 80,787.30 (+76.54, +0.09%) and the Nifty 50 at 24,773.15 (+32.15, +0.13%). Nifty Midcap 100 +0.50%; Nifty Smallcap 100 +0.16%. India VIX ticked up to 10.83 (+0.46%). Sectorally, Nifty Auto +3.3% led; Nifty IT −0.94% lagged. Provisional flows showed FIIs −₹2,169 crore; DIIs +₹3,014 crore.
Key Drivers :
GST pass-through lifts autos: OEMs announced price cuts post rate rationalisation; autos surged while broader indices held gains despite late selling.
Flows & settlements: FIIs net sold while DIIs bought; currency, money, and G-sec markets were closed, and Monday/Tuesday equity settlements will clear on Wednesday.
Global tone supportive: Softer U.S. data kept Fed-cut hopes alive; metals rallied on China supply signals; broker upgrades aided steel names.
Today’s Top Stories:
Infosys buyback on the table: Board to consider equity repurchase on Sep 11; stock lagged IT peers.
Hero hires new CEO: Harshavardhan Chitale to take charge Jan 5, 2026; EV push remains priority.
Tata Motors cuts car prices: Passing full GST benefits from Sep 22; shares up ~3%.
17 GW renewables lose grid slots: CTUIL revokes access for delayed projects; sector reaction mixed.
Mankind Pharma R&D step-up: CDSCO clears Phase-I trial for autoimmune candidate; stock up modestly.
TOP STORIES
1. Infosys board to weigh share buyback on Sept 11
DALL-E
Financial development: Infosys said its board will consider a buyback of equity shares on Sep 11, its first since the ₹9,300-crore 2022 program.
Strategic implication: A repurchase would signal balance-sheet strength and could lift per-share metrics while management navigates a weak global IT demand cycle.
Market reaction: Infosys closed at approximately ₹1,432, underperforming the index amid sector weakness.
After hinting at capital return, Infosys will consider a buyback on Sep 11. Signal of balance sheet strength or just optics during a weak IT cycle. Your take on the potential buyback
2. Hero MotoCorp names Harshavardhan Chitale as CEO (effective Jan 5, 2026)
DALL-E
Leadership change: The board appointed Harshavardhan Chitale (ex-Signify/Philips Lighting) as CEO, succeeding acting CEO Vikram Kasbekar. Effective Jan 5, 2026.
Operational read-through: Management framed the move as accelerating the push into EVs and emerging mobility, alongside core ICE portfolio execution.
Market reaction: Stock was flat to marginally higher post-announcement, with broader auto strength overshadowing single-name moves.
Hero MotoCorp names Harshavardhan Chitale as CEO effective Jan 5, 2026. Can leadership change accelerate EV and new mobility while protecting the ICE core
3. Tata Motors passes on GST cut; passenger vehicles to be cheaper from Sept 22
DALL-E
KFinancial development: Company will cut prices by up to ~₹1.45–1.55 lakh across several models as it passes the full GST reduction to buyers from Sep 22.
Strategic implication: Anticipated demand pull-forward into the festive season; improves affordability across hatch/SUV segments and could aid share gains.
Market reaction: Tata Motors rose ~3.2%; Nifty Auto +3.3% led sectoral gains.
Tata Motors will pass through the GST cut and lower prices by up to about 1.45 to 1.55 lakh from Sep 22. Demand pull forward or margin squeeze
4. CTUIL revokes grid access for ~17 GW of delayed clean-energy projects
DALL-E
Financial development: India cancelled long-term grid access for ~17 GW of delayed renewable projects, impacting developers such as Adani Green, ReNew, NTPC, JSW Energy, and others.
Strategic implication: Move prioritises operational/near-ready capacity amid record power demand and aims to free transmission corridors; some firms have appealed at CERC.
Market reaction: Renewable names were mixed; investors weighed project pipeline risk against long-term capacity targets. (No broad-based price swing cited intraday.)
CTUIL cancelled long term grid access for delayed renewable projects across multiple developers. Does prioritizing near ready capacity improve reliability or raise pipeline risk
5. Mankind Pharma gets CDSCO nod for Phase-I trial of autoimmune drug
DALL-E
Financial development: CDSCO approved Phase-I clinical trial for Mankind’s in-house biologic targeting autoimmune conditions—its first such program in this category.
Strategic implication: Marks a step-up in R&D depth and potential pipeline diversification beyond branded generics, with optionality in specialty therapies.
Market reaction: Shares were modestly higher alongside a firm broader market; the street will watch trial milestones and timelines.
CDSCO cleared Mankind Pharma to begin Phase 1 for an in house biologic in autoimmune therapy. Early stage optionality or long pathway risk
GYAANI HOT TAKES
Disclaimer:
The IndiaStox Research Hackathon is intended for educational and community engagement purposes only. Submissions do not constitute investment advice, nor should they be construed as recommendations to buy or sell any securities.
By participating in the IndiaStox Research Hackathon and submitting content, you grant IndiaStox a worldwide, royalty-free, perpetual, and irrevocable license to use, reproduce, modify, publish, distribute, and display your submission, whether in whole or in part, across its digital platforms and in promotional materials. This license extends to both commercial and non-commercial purposes, including content seeding, editorial use, and advertising.
By submitting your work, you confirm that it is your original creation and that you have the right to grant the above license.
